C61 Malignant neoplasm of prostate

Billable ICD-10-CM code, FY2026.

Excludes1 (never code together)

• malignant neoplasm of seminal vesicle (C63.7)

Use additional code

• code, if applicable, to identify:
• hormone sensitivity status (Z19.1-Z19.2)
• rising PSA following treatment for malignant neoplasm of prostate (R97.21)

Applies from C61 Malignant neoplasm of prostate

Excludes1 (never code together)

• malignant neoplasm of seminal vesicle (C63.7)

Use additional code

• code, if applicable, to identify:
• hormone sensitivity status (Z19.1-Z19.2)
• rising PSA following treatment for malignant neoplasm of prostate (R97.21)

Risk adjustment (HCC)

• CMS-HCC V28: HCC 23 — Prostate, Breast, and Other Cancers and Tumors
• CMS-HCC V22: HCC 12 — Breast, Prostate, and Other Cancers and Tumors
• RxHCC V08: HCC 22 — Prostate, Breast, Bladder, and Other Cancers and Tumors
• ESRD V24: HCC 12

MS-DRG index

Defines the logic of DRG(s) 715-716 in MDC 12.

Approximate ICD-9-CM (GEMs)

• 185 Malignant neoplasm of prostate

Code annotations containing back-references to C61

Back-references to C61

• Type 2 Excludes: N40 Benign prostatic hyperplasia ("malignant neoplasm of prostate (C61)")
• Code First: Z79.81 Long term (current) use of agents affecting estrogen receptors and estrogen levels ("malignant neoplasm of prostate (C61)")

Back-references to C61

• Type 2 Excludes: N40 Benign prostatic hyperplasia ("malignant neoplasm of prostate (C61)")
• Code First: Z79.81 Long term (current) use of agents affecting estrogen receptors and estrogen levels ("malignant neoplasm of prostate (C61)")

Diagnosis Index entries for C61

• Adenocarcinoma › duct › unspecified site › male
• Carcinoma (malignant) › endometrioid › unspecified site › male
• Cystadenocarcinoma › endometrioid › unspecified site › male

Nearby codes

• C61 Malignant neoplasm of prostate (this code)